Device Trial Radar · NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
363
Planned (sponsor's estimate)
Start
Dec 3, 2024
Primary completion
May 1, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- OSE ImmunotherapeuticsNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Exystat; GeneDx
- First posted
- Jun 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Conditions
- Patients With Non-Small Cell Lung Cancer
Interventions
OSE2101Drug
OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
DocetaxelDrug
Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
NGS HLAA2 assayDevice
Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
Primary outcomes
What the sponsor says the trial is designed to measure.
- OS defined as time from randomization to deathTime frame: From randomization date through study completion, an average of 3 years
Locations
207 sites in 14 countries. Site status is shown where the registry gives one.
Clinical Research Advisors, LLC
Beverly Hills, California · Recruiting
Clinical Research Advisors - Encino
Encino, California · Active not recruiting
Clinical Research Advisors - West Hollywood
Los Angeles, California · Active not recruiting
204 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.